Lancet HIV

Article	Citations
Optimising anal cancer screening through risk stratification	432
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	163
How do we prevent anal cancer in people living with HIV?	136
The Australian AIDS crisis through the eyes of volunteers	133
HIV and COVID-19: juxtaposition of two pandemics	126
Evidence supports use of on-demand PrEP for HIV prevention	120
Lung cancer in people living with HIV	118
Transplant donation without discrimination	116
Argentina updates HIV laws	116
How much could long-acting PrEP cost in South Africa?	107
Steps toward quick and equitable roll-out of lenacapavir	105
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV	98
Controversial chronicler of LGBTQ rights	98
Correction to Lancet HIV 2022; 9: e791–800	81
A moment of reckoning	76
Are we ready for long-acting HIV treatment for adolescents?	69
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	68
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	67
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	64
Lenacapavir: an attractive option, but proceed with caution	62
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	62
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	60
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	60
Risk estimation in HIV reveals our usual blind spots	59
All roads lead to Westminster: the infected blood scandal	57

Redefining care: injectable HIV treatment for adolescents	55
Making America unhealthy again	55
Equitable access to long-acting PrEP on the way?	54
Recent gay Black history in the UK	53
Reducing HIV transmission in British Columbia, Canada	51
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	49
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys	48
Suicide prevention research is crucial to achieving health equity for people with HIV	47
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:	47
Game-changing study of second-line HIV treatment	46
Unheard testimony	46
Gains and gaps: addressing HIV in diverse sex worker groups	46
Integration of sexual health and HIV services	45
Dolutegravir in neonates: finally we are getting there!	45
Sex as a biological variable in HIV-1 and schistosome co-infection	44
Preventing tuberculosis in advanced HIV disease	43
WHO recommends lenacapavir for HIV prevention	43
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	42
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	41
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	41
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	41
Standardisation of monitoring routines for new long-acting antiretrovirals in development	41
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	40
An eventful conference	37
HIV self-testing: from availability to strategic deployment	37
Eliminating HIV in the UK among men who have sex with men	36
Preventing sexually transmitted infections in the age of PrEP	35
Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/	35
How can Africa sustain its HIV response amid US aid cuts?	35
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	34
25 years of the Alliance for Public Health in Ukraine	34
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	31
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	31
Advancing the prevention and treatment of HIV in children: priorities for research and development	31
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	30
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	30
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	29
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	28
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	28
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis	28
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	27
The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	27
Reduction of HIV reservoir after stem cell transplantation	27
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	26
Highlights from the 25th International AIDS Conference	26
Coffee with IAS President Beatriz Grinsztejn	26
Effects of self-testing on HIV outcomes in west Africa	26
Implementation of PrEP in Latin America	25
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	25
Correction to Lancet HIV 2025; 12: e691–700	24

Closing the gap to UNAIDS 95-95-95: Lesotho's success story	23
Crucial need for improved pharmacovigilance in pregnancy	23
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	23
Second-line HIV treatments for adults in LMICs	23
Optimised second-line regimens in the public health approach	23
Can treatment-as-prevention and PrEP reduce HIV incidence?	23
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	23
MSM and HIV in the Middle East and north Africa	23
Intersectional climate justice, health equity, and HIV	23
Metabolic implications and safety of dolutegravir use in pregnancy	22
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	22
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	22
No woman left behind: achieving cervical cancer elimination among women living with HIV	22
Addressing partner violence to end infant HIV infection	21
Complex response to HIV and tuberculosis in South Sudan	21
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	21
Cigarette smoking in PrEP recipients: a challenge and an opportunity	20
Point-of-care testing to achieve paediatric 95-95-95 targets	20
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	20
Can COVID-19 changes reduce stigma in African HIV clinics?	20
The HIV vaccine quest: ethical and implementation challenges	20
Need for clear inclusion criteria in reviews of antiretroviral treatments	20
Treatment of HIV and HBV coinfection	20
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	19
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	19
A field of possibilities for paediatric HIV	19
Metabolic syndrome and cardiovascular risk on INSTIs	19
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	18
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	18
Unified health surveys for integrated health systems	18
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	18
Integrase inhibitors hand us a new HIV clinical puzzle	18
HIV treatment in Russia on the brink of crisis	18
HERO—providing support for those engaged in chemsex	18
Long-acting PrEP for adolescent girls and young women	18
Activists step in to deliver PEP and PrEP in Mexico	18
Realising long-acting ART as first-line treatment	17
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	17
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	16
Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study	16
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	16
Critical illness due to infection in people living with HIV	16
Expanding options of child-friendly, single-tablet regimens for young children with HIV	16
Improving outcomes for children in families with HIV	16
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	16
A career dedicated to public service	16
HIV-related CNS infections: translating DREAMM into reality	15
Tajikistan faces a crucial moment in HIV/AIDS response	15
Correction to Lancet HIV 2025; 12: e473–84	15
HIV viral suppression is key to healthy longevity	15
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	15
Correction to Lancet HIV 2023; 10: e424–26	15
Ending HIV in Chicago by 2030	15
Expanding PrEP treatment options with a potent anti-HIV antibody	15
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	15
Zvandiri—when medicines alone are not enough	14
Inherited fear: 40 years of HIV/AIDS in the UK	14
Enhancing HIV prevention through systematic community engagement, learning, and response	14
A research framework to support re-engagement and continuous engagement in HIV care	14
Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study	13
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	13
PEPFAR reauthorisation hangs in the balance	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	13
Long-acting PrEP: new opportunities with some drawbacks	12
Reimagining HIV prevention with artificial intelligence	12
Expansion of PrEP and PEP services in China	12
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	12
Where does doravirine fit in current antiretroviral therapy?	12
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	12
Correction to Lancet HIV 2025; 12: e712–21	12
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	12
Equitable access to PrEP is essential to reap its benefits	11
Putting people first in communication about HIV	11
UK and US militaries update HIV policies	11
Defining principles for a choice-based approach to HIV prevention	11
Screening for chlamydia and incidence of symptomatic infections	11
Home delivery of ART: could this be a reality in South Africa?	11
HIV prevention for young African women is about choice	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11
Response to Thailand's commitment to support community-led HIV services	10

Mexican perspective on the Mosaico HIV vaccine trial	10
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	10
The urgent need for opioid agonist treatment in Russia	10
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	10
What future for HIV vaccines?	10
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	10
Low-cost point-of-care urine test to enhance PrEP adherence	10
Dolutegravir dosing with rifampicin	10
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	10
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	10
Legislation threat to services for LGBTQ+ people in Georgia	10
COP27 Climate Change Conference: urgent action needed for Africa and the world	10
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	9
Correction to Lancet HIV 2025; 12: e616–26	9
Mental health needs of adolescents with HIV in Africa	9
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	9
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	9
Elton John AIDS Foundation plugging gaps in HIV funding	9
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	9
Using art to promote HIV prevention and highlight inequalities	9
Due south: navigating volatile health research landscapes	9
Thailand's progress toward long-acting PrEP	9
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	9
Russia spiralling into an HIV crisis	9
Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries	9
Artificial intelligence in HIV research, policy, and clinical care	9
Use of mobile phone data in HIV epidemic control	9
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	9
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	8
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	8
The 3 moments for U=U education	8
UK boosts HIV testing efforts	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	8
Closeted life of a Hollywood giant	8
Gender-affirming hormone therapy is a crucial component of HIV care	8
PrEParing to curb the HIV epidemic in Zambia	8
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	8
Understanding and managing disordered sleep in people with HIV	8
Do we need routine integrase resistance testing before starting antiretroviral therapy?	8
Hospitalisation trends in people with HIV: what is our aim?	8
Another step forward in implementing long-acting PrEP	8
Correction to Lancet HIV 2025; published online April 3. https://doi.org/10.1016/S2352-3018(25)00097-9	7
Social media helping younger adults combat HIV stigma	7
Documenting the UK's 40-year battle with HIV/AIDS	7
HIV prevalence, risk behaviours, and cascade of care among men who have sex with men in Iran: a nationwide, cross-sectional, biobehavioural survey	7
Correction to Lancet HIV 2024; 11: e793–94	7
IPV prevention must be integrated into HIV care	7
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine	7
HIV in Sudan's war: a silent emergency amid a protracted conflict	7
Addressing the evidence gap for HIV prevention in pregnancy	7
Long-acting antiretrovirals: research and implementation considerations in Africa	7
From early alarm to gradual control of monkeypox	7
Community and care in MENA's HIV crisis	7
Viral view: 100 years of transmission	7
INSTI era resistance: emerging concern or marginal issue?	6
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE	6
Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021	6
Cabotegravir injectable PrEP approved in England and Wales	6
Correction to Lancet HIV 2024; 11: e31–41	6
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns	6
Benefits of early ART initiation on mortality among people with HIV	6
Looking beyond facilities to eliminate vertical transmission	6
Discrimination major challenge to HIV control in Kyrgyzstan	6
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium	6
Emerging landscape for long-acting HIV prevention	6
Brazil eliminates vertical transmission of HIV	6
HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort study	6
Mentor mothers stopping vertical transmission in Kenya	6
Correction to Lancet HIV 2024; 11: e64–65	6
Correction to Lancet HIV 2025; 12: e130–42	6
Untangling the causal ties between antiretrovirals and obesity	6
Need for clear inclusion criteria in reviews of antiretroviral treatments – Authors' reply	6
Denying access to long-acting injectable treatment for HIV: an open letter	6
HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study	6
UNAIDS cuts leave enormous gap in global HIV response	6
US funding for HIV at risk again	6
Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysis	6
Projecting changes in demographics and causes of death in people with HIV in western Europe from 2025 to 2050: a mathematical modelling study	6
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial	6
Declaration commits to ending AIDS in children	6
Going the last mile in the USA	6
Intergenerational dialogue on HIV and ageing	6
Highlights from CROI 2024	5
Highlights of the 19th European AIDS Conference	5
Improving quality of interpersonal care in HIV programmes	5
LGBTQ+: a community united by stigma	5
Love, resilience, and community in the Chilean desert	5
Supporting Poland's LGBT+ community through thick and thin	5
HIV support for Global Majority communities in London	5
Preventing HIV in young women in Africa	5
Highlights from CROI 2025	5
Adapting the UK's HIV response to a changing epidemic	5
Is the USA on track to end the HIV epidemic?	5
HIV infection and engagement in the care continuum among migrants and refugees from Venezuela in Colombia: a cross-sectional, biobehavioural survey	5